<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput xmlns:ns2="local" id="55997"><DrugName>tabalumab</DrugName><DrugNamesKey><Name id="42950678">tabalumab</Name></DrugNamesKey><DrugSynonyms><Name><Value>LY-2127399</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>anti-BAFF humanized monoclonal antibody (rheumatoid arthritis/lupus), Eli Lilly</Value></Name><Name><Value>BAFF antibody (RA/lupus), Eli Lilly</Value></Name><Name><Value>tabalumab</Value><Types><Type>USAN</Type><Type>INN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="17810">Eli Lilly &amp; Co</CompanyOriginator><CompaniesSecondary><Company id="17810">Eli Lilly &amp; Co</Company></CompaniesSecondary><CrossReferences><SourceEntity id="55997" type="Drug"><TargetEntity id="631950" type="siDrug">Tabalumab</TargetEntity></SourceEntity><SourceEntity id="17810" type="Company"><TargetEntity id="4295904414" type="organizationId">Eli Lilly and Co</TargetEntity></SourceEntity><SourceEntity id="1828" type="ciIndication"><TargetEntity id="C90.0" type="ICD10"></TargetEntity><TargetEntity id="10028228" type="MEDDRA"></TargetEntity><TargetEntity id="D009101" type="MeSH"></TargetEntity><TargetEntity id="29073" type="ORPHANET"></TargetEntity><TargetEntity id="-18870694" type="omicsDisease"></TargetEntity><TargetEntity id="710" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="213" type="ciIndication"><TargetEntity id="G35" type="ICD10"></TargetEntity><TargetEntity id="10028245" type="MEDDRA"></TargetEntity><TargetEntity id="D009103" type="MeSH"></TargetEntity><TargetEntity id="-1241225595" type="omicsDisease"></TargetEntity><TargetEntity id="112" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="291" type="ciIndication"><TargetEntity id="10039073" type="MEDDRA"></TargetEntity><TargetEntity id="D001172" type="MeSH"></TargetEntity><TargetEntity id="-1391695545" type="omicsDisease"></TargetEntity><TargetEntity id="749" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="318" type="ciIndication"><TargetEntity id="M32" type="ICD10"></TargetEntity><TargetEntity id="10042945" type="MEDDRA"></TargetEntity><TargetEntity id="D008180" type="MeSH"></TargetEntity><TargetEntity id="-1461472531" type="omicsDisease"></TargetEntity><TargetEntity id="731" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="55684" type="Action"><TargetEntity id="4126" type="Mechanism">Anti-Globo H</TargetEntity><TargetEntity id="3131" type="Mechanism">Anti-Thomsen-Friedenreich Antigen (CD176)</TargetEntity><TargetEntity id="3601" type="Mechanism">Anti-Tn Antigen</TargetEntity><TargetEntity id="3993" type="Mechanism">Anti-Stage-Specific Embryonic Antigen (SSEA)-5 (Anti-H Type-1 Antigen)</TargetEntity><TargetEntity id="3294" type="Mechanism">Drugs Targeting Cancer Associated Antigens</TargetEntity></SourceEntity><SourceEntity id="12770" type="Action"><TargetEntity id="1609" type="Mechanism">Anti-BlyS (BAFF; TNFSF13B)</TargetEntity></SourceEntity><SourceEntity id="2953" type="Action"><TargetEntity id="802" type="Mechanism">Mediator Release Inhibitors</TargetEntity><TargetEntity id="775" type="Mechanism">Antiinflammatory Drugs</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="C3">Phase 3 Clinical</PhaseTerminated><RegulatoryDesignations><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsSecondary><Indication id="1828">Multiple myeloma</Indication><Indication id="213">Multiple sclerosis</Indication><Indication id="291">Rheumatoid arthritis</Indication><Indication id="318">Systemic lupus erythematosus</Indication></IndicationsSecondary><ActionsPrimary><Action id="12770">B-lymphocyte stimulator ligand inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="2953">Anti-inflammatory</Action><Action id="55684">Anticancer antibody</Action><Action id="396">Immunosuppressant</Action></ActionsSecondary><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="740">Infusion</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="647">Subcutaneous formulation</Technology><Technology id="169">Monoclonal antibody humanized</Technology><Technology id="1263">Immuno-oncology</Technology></Technologies><EphmraCodes><Ephmra><Code>L4</Code><Name>IMMUNOSUPPRESSIVE AGENTS</Name></Ephmra></EphmraCodes><LastModificationDate>2018-01-16T21:41:52.000Z</LastModificationDate><ChangeDateLast>2017-09-29T00:00:00.000Z</ChangeDateLast><AddedDate>2006-08-24T17:52:56.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="17810" linkType="Company"&gt;&lt;/ulink&gt;&lt;ulink linkID="17810" linkType="Company"&gt;Eli Lilly&lt;/ulink&gt; was developing tabalumab (LY-2127399), an anti-BAFF humanized monoclonal antibody, for the potential treatment of autoimmune diseases, primarily systemic lupus erythematosus (SLE)   [&lt;ulink linkID="970293" linkType="Reference"&gt;970293&lt;/ulink&gt;], [&lt;ulink linkID="914053" linkType="Reference"&gt;914053&lt;/ulink&gt;], [&lt;ulink linkID="914049" linkType="Reference"&gt;914049&lt;/ulink&gt;], [&lt;ulink linkID="1002155" linkType="Reference"&gt;1002155&lt;/ulink&gt;], [&lt;ulink linkID="1139142" linkType="Reference"&gt;1139142&lt;/ulink&gt;]. However, in October 2014, the drug was discontinued due to insufficient efficacy in two pivotal phase III trials (ILLUMINATE 1 and 2) [&lt;ulink linkID="1599245" linkType="Reference"&gt;1599245&lt;/ulink&gt;]. Later in October 2014, the company stated that the drug was lost through attrition [&lt;ulink linkID="1604963" linkType="Reference"&gt;1604963&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In December 2010, worldwide phase III trials in SLE were initiated [&lt;ulink linkID="1139142" linkType="Reference"&gt;1139142&lt;/ulink&gt;]. A further phase III trial of a prefilled syringe in patients with lupus was initiated in January 2014 [&lt;ulink linkID="1576357" linkType="Reference"&gt;1576357&lt;/ulink&gt;]. In February 2011, an IND for tabalumab was accepted by the Chinese SFDA, presumably for the treatment of SLE; in June 2012, supplemental material was requested to conclude the review [&lt;ulink linkID="1342685" linkType="Reference"&gt;1342685&lt;/ulink&gt;], [&lt;ulink linkID="1397612" linkType="Reference"&gt;1397612&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Tabalumab was previously being developed for rheumatoid arthritis  (RA) multiple sclerosis (MS) and multiple myeloma (MM). By January 2010, worldwide, phase III RA studies had begun  [&lt;ulink linkID="1139147" linkType="Reference"&gt;1139147&lt;/ulink&gt;]. However, in December 2012, the FLEX-M study was discontinued due to insufficient efficacy [&lt;ulink linkID="1350189" linkType="Reference"&gt;1350189&lt;/ulink&gt;]. In February 2013, Lilly discontinued further development for RA following an interim futility analysis of a second phase III trial (FLEM-V); all tabalumab RA clinical studies were terminated [&lt;ulink linkID="1366731" linkType="Reference"&gt;1366731&lt;/ulink&gt;]. In April 2009, a phase II trial in relapsing-remitting MS was initiated; the trial was completed in June 2012 [&lt;ulink linkID="1002155" linkType="Reference"&gt;1002155&lt;/ulink&gt;], and no further development has been reported in this indication. In July 2012, a phase II/III trial in MM commenced, which completed in  July 2014 [&lt;ulink linkID="1347034" linkType="Reference"&gt;1347034&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;In November 2012, the FDA granted tabalumab Orphan Drug designation for the treatment of MM [&lt;ulink linkID="1347031" linkType="Reference"&gt;1347031&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;In March 2013, approval was expected in May 2015 [&lt;ulink linkID="1397062" linkType="Reference"&gt;1397062&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;End stage renal disease&lt;/subtitle&gt;In November 2015, clinical data were presented from a phase IIa, single-arm, open-label, exploratory study, at ASN's Kidney Week 2015 in San Diego, CA. Patients were administered tabalumab in loading dose (240 mg sc; n = 18) and maintenance dose (120 mg sc q4w; n = 18). Significant reductions in calculated panel reactive antibody of 92.5, 90.5, 91.0, 90.4, 92.2, 91.1 and 91.1 was observed at weeks 8, 16, 24, 32, 52, 64 and 76, respectively. Tabalumab reduced total, naive and transitional B cells and increased memory B cells at week 36 [&lt;ulink linkID="1708458" linkType="Reference"&gt;1708458&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Systemic lupus erythematosus&lt;/subtitle&gt;In November 2015,  Pooled data were presented from the analysis of two 52-week, randomized, double-blinded, placebo-controlled, phase III studies (BCDS and BCDT) performed to evaluate the safety and efficacy of tabalumab, for the treatment of systemic lupus erythematosus, at the 79th ACR Annual Meeting in San Francisco, CA. Serum creatinine, glomerular filtration rate and urine protein/creatinine ratio was 0.54, 0.11 an d 0.31 micromol/l, 0.17, 0.63 an d0.38 ml/min/bsa and 0.44, -0.30 and 1.87 mg/mmol, respectively from both the studies  [&lt;ulink linkID="1709818" linkType="Reference"&gt;1709818&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2015, clinical data were presented at ASN's Kidney Week 2015 in San Diego, CA. A two 52-week, randomized, double-blinded, placebo (PBO)-controlled phase III trials with tabalumab (120 mg, sc) showed, the intent-to-treat (ITT) population serum creatinine (SCr), glomerular filtration rate (GFR) and uPCR with q2w, q4w and placebo were 0.54, 0.11, 0.31 and 0.17, 0.63, 0.38 and 0.44, -0.30, 1.87, respectively. In ITT patients with a baseline uPCR &amp;gt;20 mg/mmol, SCr, GFR and uPCR were 1.68, 1.42, 2.73 and -0.87, 0.29, -2.14 and -12.52, -9.08, -7.53 for tab q2w, q4w and placebo, respectively. There were no different renal adverse events in treatment arms [&lt;ulink linkID="1708443" linkType="Reference"&gt;1708443&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2015, clinical data were presented from two randomized, phase III studies (ILLUMINATE 1 and 2) at the 16th EULAR Annual European Congress in Rome, Italy. Statistically significant pharmacodynamic changes were observed for anti-dsDNA abs, C3 and C4, total serum IgG, IgM and IgA, and peripheral blood B cell number in both trials compared with placebo. In the treatment groups, pharmacodynamic changes in predefined B cell and plasma cell genes were observed  and associated with changes in anti-dsDNA abs, serum Ig and complement levels, and cell number [&lt;ulink linkID="1669849" linkType="Reference"&gt;1669849&lt;/ulink&gt;]. Further data from the analysis of the two trials were presented at the same conference. Data demonstrated that biologic activity of tabalumab was exhibited by changes in anti-double stranded DNA, complement, B cell, and Ig which was consistent with BAFF inhibition [&lt;ulink linkID="1667663" linkType="Reference"&gt;1667663&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In January 2014, a phase III trial (&lt;ulink linkID="168897" linkType="Protocol"&gt;NCT02041091&lt;/ulink&gt;) was initiated to evaluate tabalumab administered either in a prefilled syringe or via a traditional syringe in patients with lupus. The primary endpoint was pharmacokinetics. The trial was to enroll 216 patients and complete in January 2016 [&lt;ulink linkID="1576357" linkType="Reference"&gt;1576357&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2012, an open-label phase III study (&lt;ulink linkID="83112" linkType="Protocol"&gt;NCT01488708&lt;/ulink&gt;; ILLUMINATE-X) began to evaluate the long-term safety and efficacy of tabalumab in patients with lupus who had completed NCT01196091 and NCT01205438. The primary endpoint was number of adverse events. The trial was to enroll 1276 patients and complete in August 2019 [&lt;ulink linkID="1576362" linkType="Reference"&gt;1576362&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2010, a randomized, double-blind, placebo-controlled, parallel-group, worldwide, phase III trial (&lt;ulink linkID="70051" linkType="Protocol"&gt;NCT01196091&lt;/ulink&gt;; 13656; H9B-MC -BCDS; ILLUMINATE 1) was initiated to assess the safety and efficacy of sc  tabalumab  plus standard of care in patients with active SLE (expected n = 1140). The primary endpoint was the proportion of patients achieving an SLE responder index response at week 52. At that time, the study was expected to complete in February 2014. By November 2013, the completion date had been extended to July 2015; at that time, the trial was ongoing, but was no longer recruiting participants [&lt;ulink linkID="1139142" linkType="Reference"&gt;1139142&lt;/ulink&gt;]. In October 2014, data from the trial were reported, which showed that study did not meet the primary endpoint of statistically significant improvement on SRI-5 responder index response compared with standard of care therapy. At that time, the Lilly announced that development of tabalumab was discontinued [&lt;ulink linkID="1599245" linkType="Reference"&gt;1599245&lt;/ulink&gt;]. In July 2015, the trial was completed in 1164 patients [&lt;ulink linkID="1139142" linkType="Reference"&gt;1139142&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2011, a randomized, double-blind, placebo-controlled, parallel-group, worldwide, phase III trial (&lt;ulink linkID="70481" linkType="Protocol"&gt;NCT01205438&lt;/ulink&gt;; 13653; H9B-MC-BCDT; ILLUMINATE 2) began to assess the safety and efficacy of sc tabalumab plus standard of care in patients with SLE (expected n = 1140). The primary endpoint was the proportion of patients achieving an SLE responder index response at week 52. At that time, the study was expected to complete in March 2013. By November 2013, the completion date had been extended to August 2015; at that time, the trial was ongoing, but was no longer recruiting participants [&lt;ulink linkID="1139141" linkType="Reference"&gt;1139141&lt;/ulink&gt;]. In October 2014, data from the trial were reported, which showed that only the higher dose of tabalumab met the primary endpoint of statistically significant improvement on SRI-5 responder index response. At that time, the Lilly announced that development of tabalumab was discontinued [&lt;ulink linkID="1599245" linkType="Reference"&gt;1599245&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Multiple myeloma&lt;/subtitle&gt;In July 2012, a randomized, double-blind, placebo-controlled, phase II/III trial (&lt;ulink linkID="87573" linkType="Protocol"&gt;NCT01602224&lt;/ulink&gt;; 14199, H9S-MC-JDCG) of tabalumab (iv) in combination with &lt;ulink linkID="15954" linkType="Drug"&gt;bortezomib&lt;/ulink&gt; and dexamethasone began in patients (estimated n = 771) with previously treated MM, in the US, Canada, Mexico, Brazil, Europe, Korea and Taiwan. The trial completed in July 2014 [&lt;ulink linkID="1347034" linkType="Reference"&gt;1347034&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In March 2008, a non-randomized,   open-label, single-group assignment phase I trial (&lt;ulink linkID="25592" linkType="Protocol"&gt;NCT00689507&lt;/ulink&gt;; H9S-MC-JDCF[a]) of iv tabalumab in combination with iv &lt;ulink linkID="15954" linkType="Drug"&gt;bortezomib&lt;/ulink&gt; began in patients (expected n = 50) with relapsed or refractory MM.  The primary endpoint would be pharmacokinetic/pharmacodynamic modeling of tabalumab to determine a phase II dose. The trial was expected to complete in June 2010 [&lt;ulink linkID="914049" linkType="Reference"&gt;914049&lt;/ulink&gt;]; in May 2011, data were reported from the study. The analysis suggested that 100 mg of tabalumab was the best dose, and showed that a total of 11 of 20 patients achieved a partial response or better.  Due to progressive disease, one patient discontinued at cycle 5, and died 3 months later [&lt;ulink linkID="1193025" linkType="Reference"&gt;1193025&lt;/ulink&gt;]. Similar data were presented  in June 2011, at the 47th ASCO meeting in Chicago, IL [&lt;ulink linkID="1196427" linkType="Reference"&gt;1196427&lt;/ulink&gt;].  In December 2012, data were presented from 48 patients at the 54th ASH Meeting in Atlanta, GA.  Confirmed responses included complete responses, very good partial responses (PR) and PRs in 2, 4 and 16 patients, respectively. Association of responses with lower serum BAFF of IL-6 levels was independent of tabalumab dose given. In patients treated with 100 mg tabalumab, response was associated with lower baseline serum levels of IL-10 and undetectable TNF-alpha [&lt;ulink linkID="1346177" linkType="Reference"&gt;1346177&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Rheumatoid arthritis&lt;/subtitle&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;In June 2011, a multinational, randomized, double-blind, placebo-controlled, parallel-group, phase IIIb trial (&lt;ulink linkID="71087" linkType="Protocol"&gt;NCT01215942&lt;/ulink&gt;; 13419; H9B-MC-BCDP) was initiated,  to assess the safety and efficacy of tabalumab in RA patients with or without background disease-modifying anti-rheumatic drug therapy (expected n = 1505), including patients who participated in NCT01202760, NCT01202773 and NCT01198002. The primary endpoint was the percentage of patients with ACR20 response. At that time, the study was expected to  complete in February 2019 [&lt;ulink linkID="1139151" linkType="Reference"&gt;1139151&lt;/ulink&gt;]. In December 2012, following the discontinuation of the FLEX-M study due to insufficient efficacy, enrollment of new patients in RA program was suspended [&lt;ulink linkID="1350189" linkType="Reference"&gt;1350189&lt;/ulink&gt;]. In February 2013, the study was discontinued [&lt;ulink linkID="1366731" linkType="Reference"&gt;1366731&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2011, a multinational, randomized, double-blind, placebo-controlled, parallel-group, phase III trial (&lt;ulink linkID="70368" linkType="Protocol"&gt;NCT01202773&lt;/ulink&gt;; 13732; H9B-MC-BCDV; FLEX-V) was initiated, to assess the safety and efficacy of tabalumab in patients with moderate-to-severe RA who had an inadequate response to one or more TNF-alpha inhibitors (expected n = 555). The primary endpoint was the percentage of patients with ACR20 response. At that time, the study was expected to complete in June 2014 [&lt;ulink linkID="1139152" linkType="Reference"&gt;1139152&lt;/ulink&gt;]. In December 2012, following the discontinuation of the FLEX-M study due to insufficient efficacy, enrollment of new patients in RA program was suspended [&lt;ulink linkID="1350189" linkType="Reference"&gt;1350189&lt;/ulink&gt;]. In February 2013, the study was discontinued following an interim futility analysis [&lt;ulink linkID="1366731" linkType="Reference"&gt;1366731&lt;/ulink&gt;]. In June 2014,  data were presented at EULAR 2014 Annual Meeting in Paris, France. In all the treatment groups, no significant difference in the percentage of patients achieving American college of rheumatology 20 and 50 responses, disease activity score 28-C-reactive protein and health-assessment questionnaire disability index was observed at 24 weeks [&lt;ulink linkID="1563879" linkType="Reference"&gt;1563879&lt;/ulink&gt;]. In   June 2014, similar  data were presented at same conference [&lt;ulink linkID="1566977" linkType="Reference"&gt;1566977&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2011, a phase III, multicenter, randomized, double-blind, placebo-controlled study (&lt;ulink linkID="70388" linkType="Protocol"&gt;NCT01202760&lt;/ulink&gt;; 12978; H9B-MC-BCDO; FLEX-O) was initiated, to evaluate the safety and efficacy of tabalumab in patients (estimated n = 1002) with RA with or without background disease-modifying anti-rheumatic drug (DMARD) therapy. The study was expected to complete in December 2013 [&lt;ulink linkID="1139154" linkType="Reference"&gt;1139154&lt;/ulink&gt;]. Later that month, the study was ongoing in the US, Australia, Argentina,  Bulgaria, Colombia, Croatia, Hungary, India, Japan, South Korea, Lithuania, Malaysia,  Mexico, New Zealand, Poland, Romania, Russian Federation, Slovakia, South Africa, Sri Lanka, Taiwan, Ukraine [&lt;ulink linkID="1139154" linkType="Reference"&gt;1139154&lt;/ulink&gt;]. In December 2012, following the discontinuation of the FLEX-M study due to insufficient efficacy, enrollment of new patients in RA program was suspended [&lt;ulink linkID="1350189" linkType="Reference"&gt;1350189&lt;/ulink&gt;]. In February 2013, the study was discontinued [&lt;ulink linkID="1366731" linkType="Reference"&gt;1366731&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2010, a randomized, double-blind, placebo-controlled, parallel-group, worldwide, phase III trial (&lt;ulink linkID="70205" linkType="Protocol"&gt;NCT01198002&lt;/ulink&gt;; 11352; H9B-MC-BCDM; FLEX-M) was initiated, to assess the efficacy of tabalumab in patients with moderate-to-severe RA who had an inadequate response to methotrexate (expected n = 990). The  primary endpoints were the percentage of patients with American College of Rheumatology 20% response (ACR20) at week 24, change from baseline to week 52 in van der Heijde modified total Sharp score (mTSS), and change from baseline to week 24 in health assessment questionnaire-disability index (HAQ-DI). The study was scheduled to complete in July 2015. By September 2011, the trial was also recruiting patients in countries in Europe,    Asia (including Japan), South America, South Africa, Australia and New Zealand [&lt;ulink linkID="1139147" linkType="Reference"&gt;1139147&lt;/ulink&gt;]. However, in December 2012, the study was discontinued due to insufficient efficacy [&lt;ulink linkID="1350189" linkType="Reference"&gt;1350189&lt;/ulink&gt;]. In  October 2013,  data were presented at the 77th ACR/ARHP Annual Meeting in San Diego, CA. At week 24, the rates of responders of ACR20, 50 and 70% improvements were  34, 12 and 5%, respectively, in tabalumab  120 mg q4w group (n = 320) and 34, 12 and 6%, respectively, in tabalumab 90 mg q2w group   (n = 316) versus placebo [&lt;ulink linkID="1494094" linkType="Reference"&gt;1494094&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In November 2012, the company planned to present data from an open-label extension, 52-week phase II trial at the ACR/ARHP Annual Meeting in Washington DC, later that month [&lt;ulink linkID="1339226" linkType="Reference"&gt;1339226&lt;/ulink&gt;]. The presented data showed consistent efficacy up to 52 weeks of treatment with 60 or 60/120 mg of tabalumab in 182 patients studied. No unexpected safety signals were observed, although a higher frequency of serious adverse events were observed in 60/120-mg dose patients: reductions in total B cells were consistent with prior  studies [&lt;ulink linkID="1342374" linkType="Reference"&gt;1342374&lt;/ulink&gt;]. Further data showed tabalumab  reduced total B cells, mature naïve B cells and serum Igs, and increased memory B cells. Total B cells were only partially depleted and recovered during  post treatment follow -up. Reductions in B cells or  serum Igs below the lower limit of normal did not seem to be associated with  increased frequency of infections [&lt;ulink linkID="1342966" linkType="Reference"&gt;1342966&lt;/ulink&gt;]. In February 2013, all tabalumab RA clinical studies were discontinued [&lt;ulink linkID="1366731" linkType="Reference"&gt;1366731&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2011, clinical data from a phase II, randomized, double-blind, placebo-controlled, parallel-group study of iv tabalumab in RA patients with inadequate response to TNF alpha inhibitors were presented at EULAR 2011 in London, UK. No significant difference was observed between tabalumab and placebo groups for ACR50, ACR20 and ACR70 response rates at the 16-week primary endpoint; however, a significant mean change in DAS28 was demonstrated by the 80-mg group at week 16. At weeks 6 and 9 significant efficacy was shown by tabalumab for ACR20 and ACR50, and for DAS28 at week 9 when compared with placebo [&lt;ulink linkID="1194681" linkType="Reference"&gt;1194681&lt;/ulink&gt;]. In February 2013, all tabalumab RA clinical studies were discontinued [&lt;ulink linkID="1366731" linkType="Reference"&gt;1366731&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2011, clinical data from a phase II study of subcutaneously administered tabalumab were presented at EULAR 2011 in London, UK. Meaningful dose responses for ACR20, ACR50 and EULAR28 were seen at week 24 and reached significance in the  120 mg group. For the 120 mg dose group, DAS28 measurements were significant compared with placebo at most time points from week 12 onwards. There were no deaths during the study and similar treatment-emergence adverse events occurred in all treatment arms [&lt;ulink linkID="1193007" linkType="Reference"&gt;1193007&lt;/ulink&gt;]. In February 2013, all tabalumab RA clinical studies were discontinued [&lt;ulink linkID="1366731" linkType="Reference"&gt;1366731&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2006, a randomized, double-blind, placebo-controlled, phase II trial (&lt;ulink linkID="1746" linkType="Protocol"&gt;NCT00308282&lt;/ulink&gt;; 11055; H9B-MC-BCDF) of tabalumab began in RA patients receiving methotrexate. Patients (n = 126)  would receive three iv doses (30, 60 or 160 mg) over 6 months. The primary endpoint was effectiveness of the drug as measured on the ACR20 scale at week 24. The trial  had completed by September 2008   [&lt;ulink linkID="686007" linkType="Reference"&gt;686007&lt;/ulink&gt;]. A second, similar, phase II trial (&lt;ulink linkID="16601" linkType="Protocol"&gt;NCT00689728&lt;/ulink&gt;; 11351; H9B-MC-BCDG) in RA patients (expected n = 99) receiving methotrexate, and with an additional history of inadequate response or intolerance to at least one TNF-alpha inhibitor therapy, began in June 2008. Patients would receive 30 or 80 mg   iv infusion  tabalumab over 30 minutes at 0, 3 and 6 weeks. The trial would assess efficacy using the American College of Rheumatology (ACR)50 scale, and  was expected to complete in October 2009 [&lt;ulink linkID="914053" linkType="Reference"&gt;914053&lt;/ulink&gt;]. In October 2009,  data were presented at the ACR annual meeting showing proof of concept (POC) had been acheived. Signs and symptoms in drug-treated RA patients were significantly improved without complete B lymphocyte depletion or significant  reduction in plasma IgG  or IgA levels. A significant drop in IgM    levels was observed however. No  clear trend in the nature or frequency of treatment-emergent adverse events (TEAEs) by dose was observed and these occurred similarly across groups. Ten serious adverse events (SAEs) were reported by eight patients, including a serious infection  in one drug-treated subject and in one placebo-treated subject    [&lt;ulink linkID="1063318" linkType="Reference"&gt;1063318&lt;/ulink&gt;]. By December 2009, enrollment in both studies had been completed [&lt;ulink linkID="1063247" linkType="Reference"&gt;1063247&lt;/ulink&gt;]. In February 2013, all tabalumab RA clinical studies were discontinued [&lt;ulink linkID="1366731" linkType="Reference"&gt;1366731&lt;/ulink&gt;].&lt;br&gt;&lt;/br&gt; &lt;subtitle&gt;PHASE I&lt;/subtitle&gt; In November 2014, clinical data were presented from multicenter, randomized, parallel-design, Phase I trial in patients with rheumatoid arthritis at the 78th ACR Annual Meeting in Boston, MA. Patients received single dose of tabalumab (n = 12; 30 mg, sc) or tabalumab (n= 12; 10 mg, iv infusion over 30 min). Tabalumab 20 mg, sc group showed Cmax, Tmax, AUC (0 to infinity), clearance and terminal phase t1/2 values of 1760 ng/ml, 131 h, 44700 ng.day/ml, 0.447 l/day and 8.17 days, respectively compared with tabalumab 10 mg, iv infusion group (4180 ng/ml, 0.5 h, 36,200 ng.day/ml, 0.276 l/day and 7.95 days, respectively). The bioavailability of tabalumab (20 mg, sc) was found to be 62% [&lt;ulink linkID="1608599" linkType="Reference"&gt;1608599&lt;/ulink&gt;]&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Multiple sclerosis&lt;/subtitle&gt;In April 2009, a placebo-controlled, randomized, double-blind, phase II trial (&lt;ulink linkID="52557" linkType="Protocol"&gt;NCT00882999&lt;/ulink&gt;, 12778, H9B-MC-BCDJ) began in subjects (expected n = 245) with relapsing-remitting MS in the US, Canada, Israel and Europe. Subjects were to receive sc placebo or tabalumab at doses of 4, 12, 40 and 120 mg, once every 4 or 12 weeks for 24 weeks. The primary endpoint was a reduction in cumulative total gadolinium (Gd)-enhancing MRI lesions. By June 2011, recruitment had been completed and the study completed in June 2012 [&lt;ulink linkID="1002155" linkType="Reference"&gt;1002155&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Other Studies &lt;/subtitle&gt;In November 2014, clinical data were presented from subject-blind, placebo-controlled, single-dose, Phase I trial in patients with rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE) at the 78th ACR Annual Meeting in Boston, MA. Patients with stable RA (n = 23) received a single dose of tabalumab (0.01, 0.04, 0.125, 0.5, 2 and 8 mg/kg, iv infusion) or placebo, and patients with stable SLE (n= 6) received one of two tabalumab doses (0.125 or 2 mg/kg) or placebo by iv infusion. Tabalumab 0.125 mg/kg treatment showed Cmax, AUC (0 to infinity), clearance (l/day), Vss and t1/2 values of 3290 ng/ml, 21300 ng.day/ml, 0.392 l/day, 6.07 l and 5.77 days, respectively in RA patients and 3350 ng/ml, 23,800 ng.day/ml, 0.349 l/day, 3.01 l and 5.57 days, respectively in SLE patients [&lt;ulink linkID="1608599" linkType="Reference"&gt;1608599&lt;/ulink&gt;]&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;In October 2010, the EMA's Pediatric Committee (PDCO) approved a pediatric investigation plan (PIP) [&lt;ulink linkID="1180079" linkType="Reference"&gt;1180079&lt;/ulink&gt;].  In April 2012, the PDCO agreed with a pediatric  investigation plan [&lt;ulink linkID="1282742" linkType="Reference"&gt;1282742&lt;/ulink&gt;]. In September 2014, the PDCO adopted a positive opinion on modification to the agreed PIP [&lt;ulink linkID="1595843" linkType="Reference"&gt;1595843&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Eli Lilly holds worldwide  development and marketing rights.&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="CN">China</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="318">Systemic lupus erythematosus</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-10-02T00:00:00.000Z</StatusDate><Source id="1599245" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="291">Rheumatoid arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-02-07T00:00:00.000Z</StatusDate><Source id="1366731" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="X4">Australia and New Zealand</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="291">Rheumatoid arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-02-07T00:00:00.000Z</StatusDate><Source id="1366731" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="318">Systemic lupus erythematosus</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-10-02T00:00:00.000Z</StatusDate><Source id="1599245" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="XH">Far East</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="318">Systemic lupus erythematosus</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-10-02T00:00:00.000Z</StatusDate><Source id="1599245" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="X2">Asia</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="291">Rheumatoid arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-02-07T00:00:00.000Z</StatusDate><Source id="1366731" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="291">Rheumatoid arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-02-07T00:00:00.000Z</StatusDate><Source id="1366731" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="1828">Multiple myeloma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-10-02T00:00:00.000Z</StatusDate><Source id="1599245" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="1828">Multiple myeloma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-10-02T00:00:00.000Z</StatusDate><Source id="1599245" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="1828">Multiple myeloma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-10-02T00:00:00.000Z</StatusDate><Source id="1599245" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="UA">Ukraine</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="318">Systemic lupus erythematosus</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-10-02T00:00:00.000Z</StatusDate><Source id="1599245" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="1828">Multiple myeloma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-10-02T00:00:00.000Z</StatusDate><Source id="1599245" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="1828">Multiple myeloma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-10-02T00:00:00.000Z</StatusDate><Source id="1599245" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="291">Rheumatoid arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-02-07T00:00:00.000Z</StatusDate><Source id="1366731" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="318">Systemic lupus erythematosus</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-10-02T00:00:00.000Z</StatusDate><Source id="1599245" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="XE">South America</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="291">Rheumatoid arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-02-07T00:00:00.000Z</StatusDate><Source id="1366731" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="1828">Multiple myeloma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-10-02T00:00:00.000Z</StatusDate><Source id="1599245" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="318">Systemic lupus erythematosus</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-10-02T00:00:00.000Z</StatusDate><Source id="1599245" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="1828">Multiple myeloma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-10-02T00:00:00.000Z</StatusDate><Source id="1599245" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="ZA">South Africa</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="291">Rheumatoid arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-02-07T00:00:00.000Z</StatusDate><Source id="1366731" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="XE">South America</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="318">Systemic lupus erythematosus</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-10-02T00:00:00.000Z</StatusDate><Source id="1599245" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="318">Systemic lupus erythematosus</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-10-02T00:00:00.000Z</StatusDate><Source id="1599245" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="291">Rheumatoid arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-02-07T00:00:00.000Z</StatusDate><Source id="1366731" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="CA">Canada</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="213">Multiple sclerosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-07-10T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="X5">Europe</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="213">Multiple sclerosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-07-10T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="IL">Israel</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="213">Multiple sclerosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-07-10T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="213">Multiple sclerosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-07-10T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="RO">Romania</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2006-03-28T00:00:00.000Z</StatusDate><Source id="686007" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="1828">Multiple myeloma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2008-03-31T00:00:00.000Z</StatusDate><Source id="914053" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-09-16T00:00:00.000Z</StatusDate><Source id="1139147" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-09-16T00:00:00.000Z</StatusDate><Source id="1139147" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-01-17T00:00:00.000Z</StatusDate><Source id="1139147" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="ZA">South Africa</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-09-16T00:00:00.000Z</StatusDate><Source id="1139147" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="X2">Asia</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-09-16T00:00:00.000Z</StatusDate><Source id="1139147" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="XE">South America</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-09-16T00:00:00.000Z</StatusDate><Source id="1139147" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="X4">Australia and New Zealand</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-09-16T00:00:00.000Z</StatusDate><Source id="1139147" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="213">Multiple sclerosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2009-04-30T00:00:00.000Z</StatusDate><Source id="1002155" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="213">Multiple sclerosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2009-04-30T00:00:00.000Z</StatusDate><Source id="1002155" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="IL">Israel</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="213">Multiple sclerosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2009-04-30T00:00:00.000Z</StatusDate><Source id="1002155" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="213">Multiple sclerosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2009-04-30T00:00:00.000Z</StatusDate><Source id="1002155" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1828">Multiple myeloma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-07-31T00:00:00.000Z</StatusDate><Source id="1347034" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="XE">South America</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="318">Systemic lupus erythematosus</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2010-12-31T00:00:00.000Z</StatusDate><Source id="1139142" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1828">Multiple myeloma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-07-31T00:00:00.000Z</StatusDate><Source id="1347034" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1828">Multiple myeloma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-07-31T00:00:00.000Z</StatusDate><Source id="1347034" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1828">Multiple myeloma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-07-31T00:00:00.000Z</StatusDate><Source id="1347034" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="318">Systemic lupus erythematosus</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2010-12-31T00:00:00.000Z</StatusDate><Source id="1139142" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="318">Systemic lupus erythematosus</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2010-12-31T00:00:00.000Z</StatusDate><Source id="1139142" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1828">Multiple myeloma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-07-31T00:00:00.000Z</StatusDate><Source id="1347034" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="XH">Far East</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="318">Systemic lupus erythematosus</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2010-12-31T00:00:00.000Z</StatusDate><Source id="1139142" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="UA">Ukraine</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="318">Systemic lupus erythematosus</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2010-12-31T00:00:00.000Z</StatusDate><Source id="1139142" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1828">Multiple myeloma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-07-31T00:00:00.000Z</StatusDate><Source id="1347034" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="318">Systemic lupus erythematosus</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2010-12-31T00:00:00.000Z</StatusDate><Source id="1139142" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1828">Multiple myeloma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-07-31T00:00:00.000Z</StatusDate><Source id="1347034" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="CN">China</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="318">Systemic lupus erythematosus</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-02-16T00:00:00.000Z</StatusDate><Source id="1342685" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="318">Systemic lupus erythematosus</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2010-12-31T00:00:00.000Z</StatusDate><Source id="1139142" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-01-17T00:00:00.000Z</StatusDate><Source id="1139154" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="318">Systemic lupus erythematosus</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2010-09-03T00:00:00.000Z</StatusDate><Source id="1139142" type="TRIALREG"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="17810">Eli Lilly &amp; Co</OwnerCompany><Country id="US">US</Country><Indication id="1828">Multiple myeloma</Indication><AwardedIndication>Treatment of multiple myeloma</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-11-19T00:00:00.000Z</MileStoneDate><Source id="1347031" type="CORPORATE"></Source></Row></RegulatoryDesignationStatus><Targets><Target id="PTGT-03396"><Name>B-lymphocyte stimulator ligand</Name><SwissprotNumbers><Swissprot>Q9WU72</Swissprot><Swissprot>Q9Y275</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><PatentFamilies><PatentFamily id="1237484" number="WO-03016468" title="Antagonistic anti-HTNFSF13B human antibodies"></PatentFamily><PatentFamily id="1585072" number="WO-2004016737" title="Novel hTNFSF13b protein variants"></PatentFamily><PatentFamily id="2683043" number="WO-2014028374" title="Biomarkers predictive of rheumatoid arthritis or systemic lupus erythematosus response to anti-BAFF antibody therapy"></PatentFamily><PatentFamily id="3914312" number="WO-2018009904" title="Compositions and treatment methods for cancer immunotherapy"></PatentFamily><PatentFamily id="997462" number="US-07728109" title="Antagonistic anti-hTNFSF13b human antibodies"></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="8">General interest</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Biograph 55 Inc" id="1186248"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Eli Lilly &amp; Co" id="17810"></CompanyLink><CountAsOwner>4</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>4</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Individual" id="21144"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput>